Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 08/09/2021
• Auteurs : Sigrid Le ClercLaura LombardiBernhard T BauneAzmeraw T AmareKlaus Oliver SchubertLiping HouScott R ClarkSergi PapiolMicah CearnsUrs HeilbronnerFranziska DegenhardtFasil Tekola-AyeleYi-Hsiang HsuTatyana ShekhtmanMazda AdliNirmala AkulaKazufumi AkiyamaRaffaella ArdauBárbara AriasJean-Michel AubryLena BacklundAbesh Kumar BhattacharjeeFrank BellivierAntonio BenabarreSusanne BengesserJoanna M BiernackaArmin BirnerClara Brichant-PetitjeanPablo CervantesHsi-Chung ChenCaterina ChillottiSven CichonCristiana CruceanuPiotr M CzerskiNina DalknerAlexandre DayerMaria Del ZompoJ. Raymond Raymond DepauloB EtainStéphane JamainPeter FalkaiAndreas J ForstnerLouise FrisenMark A FryeJanice M FullertonSébastien GardJulie S GarnhamFernando S GoesMaria Grigoroiu-SerbanescuPaul GrofRyota HashimotoJoanna HauserStefan HermsPer HoffmannEsther JiménezJean-Pierre KahnLayla KassemPo-Hsiu KuoTadafumi KatoJohn R KelsoeSarah Kittel-SchneiderEwa Ferensztajn-RochowiakBarbara KönigIchiro KusumiGonzalo LajeMikael LandénCatharina LavebrattSusan G LeckbandAlfonso TortorellaMirko ManchiaLina MartinssonMichael J MccarthySusan L McelroyFrancesc ColomVincent MillischerMarina MitjansFrancis M MondimorePalmiero MonteleoneCaroline M NievergeltMarkus M NöthenTomas NovákClaire O’donovanNorio OzakiUrban ÖsbyAndrea PfennigJames B PotashAndreas ReifEva ReininghausGuy RouleauJanusz K RybakowskiMartin SchallingPeter R SchofieldBarbara W SchweizerGiovanni SeverinoPaul D ShillingKatzutaka ShimodaChristian SimhandlClaire M SlaneyClaudia PisanuAlessio SquassinaThomas StammPavla StopkovaMario MajGustavo TureckiEduard VietaJulia VeehStephanie H WittAdam WrightPeter P ZandiPhilip B MitchellMichael BauerMartin AldaMarcella RietschelFrancis J McmahonThomas G SchulzeJean-Louis SpadoniWahid BoukouaciJean-Romain RichardP. Le CorvoisierCaroline BarrauJean-François ZaguryMarion LeboyerRyad Tamouza
• Organismes : Laboratoire Génomique, bioinformatique et chimie moléculaire CHU Henri Mondor [Créteil] IMRB - "Neuropsychiatrie translationnelle" [Créteil] Fondation FondaMental [Créteil] Westfälische Wilhelms-Universität Münster = University of Münster = Université de Münster [Münster, Allemagne] Melbourne Medical School [Melbourne] The Florey Institute of Neuroscience and Mental Health University of Adelaide University of Adelaide National Institutes of Health [Bethesda, MD, USA] University of Adelaide Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München University of Adelaide Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München Institut für Genetik - Universität Bonn / Institute of Genetics - University of Bonn Optimisation thérapeutique en Neuropsychopharmacologie Optimisation thérapeutique en Neuropsychopharmacologie Optimisation thérapeutique en Neuropsychopharmacologie Laboratoire Génomique, bioinformatique et chimie moléculaire Laboratoire Génomique, bioinformatique et chimie moléculaire IMRB - "Neuropsychiatrie translationnelle" [Créteil] CHU Henri Mondor [Créteil] Fondation FondaMental [Créteil]
• Publié dans Scientific Reports le 26/10/2020

---

Résumé : Abstract Bipolar affective disorder (BD) is a severe psychiatric illness, for which lithium (Li) is the gold standard for acute and maintenance therapies. The therapeutic response to Li in BD is heterogeneous and reliable biomarkers allowing patients stratification are still needed. A GWAS performed by the International Consortium on Lithium Genetics (ConLiGen) has recently identified genetic markers associated with treatment responses to Li in the human leukocyte antigens (HLA) region. To better understand the molecular mechanisms underlying this association, we have genetically imputed the classical alleles of the HLA region in the European patients of the ConLiGen cohort. We found our best signal for amino-acid variants belonging to the HLA-DRB1*11:01 classical allele, associated with a better response to Li ( p < 1 × 10 −3 ; FDR < 0.09 in the recessive model). Alanine or Leucine at position 74 of the HLA-DRB1 heavy chain was associated with a good response while Arginine or Glutamic acid with a poor response. As these variants have been implicated in common inflammatory/autoimmune processes, our findings strongly suggest that HLA-mediated low inflammatory background may contribute to the efficient response to Li in BD patients, while an inflammatory status overriding Li anti-inflammatory properties would favor a weak response.

---

Fichiers liés : s41598-021-97140-7.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 08/09/2021
• Auteurs : Loïc SalmonPierre-Yves PillainGoulven GuillouJean-Philippe Babau
• Organismes : Lab-STICC_UBO_CACS_MOCS Lab-STICC_UBO_CACS_MOCS

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 08/09/2021
• Auteurs : Loïc SalmonPierre-Yves PillainGoulven GuillouJean-Philippe Babau
• Organismes : Knowledge Learning and Information Modelling Laboratoire des sciences et techniques de l'information, de la communication et de la connaissance Laboratoire des sciences et techniques de l'information, de la communication et de la connaissance Laboratoire des sciences et techniques de l'information, de la communication et de la connaissance

---

Résumé : One key objective of Cyber-Physical System (CPS) simulation is to evaluate different CPS configurations regarding a certain user objective. First, simulation of CPS necessitates frameworks to handle heterogeneity of CPS components (the software and hardware system control, the behavior of the CPS itself and its physical environment). Then, to build simulators, designers use paradigms like FMI (Functional Mock-Up Interface) that proposes a data-driven generic interface facilitating the integration of heterogeneous models. However, in order to facilitate simulation configuration, an approach is required to drive modeling of parametric features and operational conditions. In this paper, we present CARES, a component-based and modeldriven approach to facilitate CPS simulation. CARES is applied to evaluate an Autonomous Underwater Vehicle (AUV) navigation function by simulation. The proposed models integrate both the principles of a generic simulation (integration of Component Based Software Engineering CBSE concepts and FMI paradigm) and domain specific aspects through a component-based architecture style. From a design model, a code generator builds the structural (Java or C++) code of the simulator. The generated code relies on a given run-time library for its execution and its structure facilitates integration of domain-specific code. The experiments show the effectiveness of the approach to build simulators for evaluation of different AUV configurations.

---

Fichiers liés : FDL21_paper_6 (2).pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 07/09/2021
• Auteurs : Guillaume CoutanceNicolas NesselerErwan FlecherAndré VincentelliCéline GoeminneClément DelmasJean PorterieKarine NubretMathieu PernotMichel KindoTam Hoang MinhPhilippe RouvièrePhilippe GaudardMagali MichelThomas SénageAude BoignardOlivier ChavanonMarylou ParaConstance VerdonkEdeline PelcéVlad GariboldiFrédéric AnselmePierre‐yves LitzlerKatrien BlanchartGerard BabatasiMarie BielefeldOlivier BouchotDavid HamonNicolas LelloucheXavier BailleulThibaud GenetRomain EschalierNicolas D’ostrevyMarie‐cécile BoriesRamzi Abi AkarHugues BlangyFabrice VanhuyseJean François ObadiaVincent GalandMatteo Pozzi
• Organismes : Hospices Civils de Lyon Hôpital Louis Pradel [CHU - HCL] Laboratoire Traitement du Signal et de l'Image Laboratoire Traitement du Signal et de l'Image Institut Coeur Poumon [CHU Lille] Institut Coeur Poumon [CHU Lille] Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Toulouse Hôpital Haut-Lévêque [CHU Bordeaux] Université de Bordeaux Hôpital Haut-Lévêque [CHU Bordeaux] Université de Bordeaux Hôpitaux Universitaires de Strasbourg Hôpitaux Universitaires de Strasbourg Hôpital Arnaud de Villeneuve [CHU Montpellier] Hôpital Arnaud de Villeneuve [CHU Montpellier] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Hôpital Michallon Hôpital Michallon AP-HP - Hôpital Bichat - Claude Bernard [Paris] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Hôpital de la Timone [CHU - APHM] Hôpital de la Timone [CHU - APHM] Hôpital Charles Nicolle [Rouen] Hôpital Charles Nicolle [Rouen] Université de Caen Normandie CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Université de Caen Normandie CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie CHU Dijon CHU Dijon CHU Henri Mondor [Créteil] CHU Henri Mondor [Créteil] CHU Trousseau [Tours] CHU Trousseau [Tours] CHU Clermont-Ferrand CHU Clermont-Ferrand Hôpital Européen Georges Pompidou [APHP] Hôpital Européen Georges Pompidou [APHP] Centre Hospitalier Universitaire de Nancy Centre Hospitalier Régional Universitaire de Nancy Centre Hospitalier Universitaire de Nancy Centre Hospitalier Régional Universitaire de Nancy Hospices Civils de Lyon Hôpital Louis Pradel [CHU - HCL] Laboratoire Traitement du Signal et de l'Image Hôpital Louis Pradel [CHU - HCL]
• Publié dans ESC Heart Failure le 04/04/2018

---

Résumé : Aims: Despite regularly updated guidelines, there is still a delay in referral of advanced heart failure patients to mechanical circulatory support and transplant centres. We aimed to analyse characteristics and outcome of non-inotrope-dependent patients implanted with a left ventricular assist device (LVAD).Methods and results: The ASSIST-ICD registry collected LVAD data in 19 centres in France between February 2006 and December 2016. We used data of patients in Interagency Registry for Mechanically Assisted Circulatory Support Classes 4-7. The primary endpoint was survival analysis. Predictors of mortality were searched with multivariable analyses. A total of 303 patients (mean age 61.0 ± 9.9 years, male sex 86.8%) were included in the present analysis. Ischaemic cardiomyopathy was the leading heart failure aetiology (64%), and bridge to transplantation was the main implantation strategy (56.1%). The overall likelihood of being alive while on LVAD support or having a transplant at 1, 2, 3, and 5 years was 66%, 61.7%, 58.7%, and 55.1%, respectively. Age [hazard ratio (HR) 1.03, 95% confidence interval (CI) 1.00-1.05; P = 0.02], a concomitant procedure (HR 2.32, 95% CI 1.52-3.53; P < 0.0001), and temporary mechanical right ventricular support during LVAD implantation (HR 2.94, 95% CI 1.49-5.77; P = 0.002) were the only independent variables associated with mortality. Heart failure medications before or after LVAD implantation were not associated with survival.Conclusion: Ambulatory heart failure patients displayed unsatisfactory survival rates after LVAD implantation. A better selection of patients who can benefit from LVAD may help improving outcomes.

---

Fichiers liés : 2021 Baudry et al;, Characteristics and outcome.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 06/09/2021
• Auteurs : Laurence SalleClaire MillotteMarion VergonjeanneMichel Druet-CabanacMarie PerrierMartine GravelatMonique Dupont-CuisinierCatherine Le FlahecJean- Claude DesportFayemendy PhilippePierre Jésus
• Organismes : Service de Médecine interne B, Endocrinologie, Diabète, Maladies métaboliques [CHU Limoges] Neuroépidémiologie Tropicale Neuroépidémiologie Tropicale Service de Santé au Travail [CHU Limoges] Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges] Neuroépidémiologie Tropicale Neuroépidémiologie Tropicale Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges] Neuroépidémiologie Tropicale Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges]
• Publié dans Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity le 31/10/2020

---

Résumé : Purpose: Obesity is a public health problem worldwide. The eating habits of French workers need to be clarified. In particular, tachyphagia (meal lasting < 15 min) promotes weight gain. The present study aimed to investigate the presence of tachyphagia at lunchtime, the factors associated with tachyphagia, and the relationship between tachyphagia and obesity among workers. Methods: This cross-sectional study was conducted between January and May 2016 in five departments of occupational medicine. An anonymous self-administered questionnaire was used to gather general declarative data, such as weight and height (to calculate body mass index [BMI]) and information about lunchtime habits, including the time spent eating. Results: A total of 415 workers with a mean age of 41.1 ± 12.6 years were included. The mean BMI was 23.8 ± 4.6 kg/m2, and the prevalence of obesity was 15.9%. Tachyphagia occurred in 20.3% of the cases and was more frequent in younger workers. Multivariate analysis revealed that skipping meals, eating standing up, and eating fast food were positively associated with tachyphagia (p = 0.015, p = 0.028, and p = 0.027, respectively). Older age and eating with colleagues/friends were negatively associated with tachyphagia (p = 0.003 and p < 0.0001, respectively). No significant association was observed between tachyphagia and obesity. Conclusion: Our study provides important information about the lunchtime habits of workers. Maintaining commensality is crucial, particularly in young workers. Companies should play a role in organising their employees' lunch breaks. Level III Evidence obtained from well-designed cohort or case-control analytic studies.

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 06/09/2021
• Auteurs : Gilles MartelPierre MischlerDaphné DurantJean-Philippe Choisis
• Organismes : Biodiversité agroécologie et aménagement du paysage Institut de l'élevage Domaine expérimental de Saint-Laurent-de-la-Prée Systèmes d'élevage méditerranéens et tropicaux

---

Fichiers liés : OWC2020-SCI-666-preview-2.pdf

---

Source

---

• Type de publi. : Rapport
• Date de publi. : 06/09/2021
• Auteurs : . Comité Scientifique Du Haut Conseil Des BiotechnologiesFrédérique AngevinClaude BagnisAvner Bar-HenMarie-Anne BarnyPascal BoireauThierry BrévaultBruno ChauvelCécile CollonnierDenis CouvetElie DassaHubert de VerneuilClaudine FranchePhilippe GuercheJoël GuillemainGuillermina Hernandez-RaquetJamal KhalifeBernard KlonjkowskiMarc LavielleValérie Le CorreFrançois LefèvreOlivier LemaireDidier LereclusRémy MaximilienEliane MeursNadia NaffakhDidier NégreSergio OchattJean-Christophe PagesXavier RaynaudCatherine Regnault-RogerMichel M. RenardTristan RenaultPatrick SaindrenanPascal SimonetMarie-Bérengère TroadecBernard E. VaissièreJean-Luc Vilotte
• Organismes : Haut Conseil des Biotechnologies Unité Impacts Ecologiques des Innovations en Production Végétale Haut Conseil des Biotechnologies Etablissement Français du Sang Haut Conseil des Biotechnologies Université Paris-Sud - Paris 11 Université Paris Descartes - Paris 5 Haut Conseil des Biotechnologies Haut Conseil des Biotechnologies Institut d'écologie et des sciences de l'environnement de Paris Direction des Ressources Humaines et du Développement Durable Haut Conseil des Biotechnologies Haut Conseil des Biotechnologies Agroécologie et intensification durables des cultures annuelles Département Performances des systèmes de production et de transformation tropicaux Haut Conseil des Biotechnologies Agroécologie [Dijon] Haut Conseil des Biotechnologies Institut Jean-Pierre Bourgin - Sciences du végétal Muséum national d'Histoire naturelle Haut Conseil des Biotechnologies Institut National de la Santé et de la Recherche Médicale Haut Conseil des Biotechnologies Institut National de la Santé et de la Recherche Médicale Haut Conseil des Biotechnologies Institut de Recherche pour le Développement Haut Conseil des Biotechnologies Haut Conseil des Biotechnologies Institut Jean-Pierre Bourgin - Sciences du végétal Agence nationale de sécurité du médicament et des produits de santé [Saint-Denis] Université de Tours Haut Conseil des Biotechnologies Laboratoire d'Ingénierie des Systèmes Biologiques et des Procédés Haut Conseil des Biotechnologies Centre National de la Recherche Scientifique Institut Pasteur de Lille Virologie UMR1161 Haut Conseil des Biotechnologies Haut Conseil des Biotechnologies Modélisation en pharmacologie de population Haut Conseil des Biotechnologies Agroécologie [Dijon] Haut Conseil des Biotechnologies Virologie et Immunologie Moléculaires Santé de la vigne et qualité du vin Haut Conseil des Biotechnologies MICrobiologie de l'ALImentation au Service de la Santé Haut Conseil des Biotechnologies Commissariat à l'énergie atomique et aux énergies alternatives Haut Conseil des Biotechnologies Institut Pasteur [Paris] Centre National de la Recherche Scientifique Haut Conseil des Biotechnologies Centre National de la Recherche Scientifique Haut Conseil des Biotechnologies Haut Conseil des Biotechnologies Agroécologie [Dijon] Université de Tours Etablissement Français du Sang Haut Conseil des Biotechnologies Haut Conseil des Biotechnologies Institut d'écologie et des sciences de l'environnement de Paris Haut Conseil des Biotechnologies Institut de Génétique, Environnement et Protection des Plantes Haut Conseil des Biotechnologies Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail Institut Français de Recherche pour l'Exploitation de la Mer Haut Conseil des Biotechnologies Haut Conseil des Biotechnologies Institut des Sciences des Plantes de Paris-Saclay Centre National de la Recherche Scientifique Haut Conseil des Biotechnologies Centre National de la Recherche Scientifique Haut Conseil des Biotechnologies Abeilles et Environnement Haut Conseil des Biotechnologies Génétique Animale et Biologie Intégrative Haut Conseil des Biotechnologies

---

Résumé : Le Haut Conseil des biotechnologies (HCB) a été saisi le 22 juin 2021 par les autorités compétentes françaises (Ministère de l'Agriculture et de l'Alimentation) d'une demande d'avis relative au dossier EFSA-GMO-NL-2020-172 de demande d'autorisation de mise sur le marché du maïs génétiquement modifié DP915635 à des fins d'importation, transformation et alimentation humaine et animale. Ce dossier a été déposé par la société Pioneer Hi-Bred International, Inc. auprès des autorités compétentes néerlandaises sur le fondement du règlement (CE) n° 1829/2003. Dans le cadre de ce règlement, l'évaluation des dossiers de demande de mise sur le marché est confiée à l'Autorité européenne de sécurité des aliments (EFSA). Les Etats membres disposent de trois mois pour envoyer leurs commentaires à l'EFSA en contribution à l'évaluation du dossier. Dans ce contexte, le HCB est invité à proposer des commentaires à destination de l'EFSA au plus tard le 07 septembre 2021.

---

Fichiers liés : 20210906avismaisdp915635cs210826.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 04/09/2021
• Auteurs : Fabien MalbetCéline BoehmAlberto Krone-MartinsAntonio AmorimGuillem Anglada-EscudéAlexis BrandekerFrédéric CourbinTorsten EnsslinAntonio FalcãoKatherine FreeseBerry HollLucas LabadieAlain LégerGary A MamonBarbara McarthurAlcione MoraMike ShaoAlessandro SozzettiDouglas SpolyarEva VillaverUmmi AbbasConrado AlbertusJoão AlvesRory BarnesAldo Stefano BonomoHervé BouyWarren R BrownVitor CardosoMarco CastellaniL. CheminHamish ClarkAlexandre C M CorreiaMariateresa CrostaAntoine CrouzierMario DamassoJeremy DarlingMelvyn B DaviesAntonaldo DiaferioMorgane FortinMalcolm FridlundMario GaiPaulo GarciaOleg GnedinAriel GoobarPaulo GordoRenaud GoullioudFabrizia GuglielmettiNigel HamblyDiana HarrisonDavid HobbsRodrigo A IbataErik HøgCarme JordiSergei KlionerA. LanconJacques LaskarMario LattanziChristophe Le Poncin-LafitteXavier LuriDaniel MichalikAndré Moitinho de AlmeidaAna MourãoLeonidas MoustakasNeil J MurrayMatthew MuterspaughMicaela OertelLuisa OstoreroJordi PortellJean-Pierre ProstAndreas QuirrenbachJean SchneiderPat ScottArnaud SiebertAntonio Da SilvaManuel SilvaPhilippe ThébaultJohn TomsickWesley TraubMiguel de Val-BorroMonica ValluriNicholas A WaltonLaura L WatkinsGlenn WhiteLukasz WyrzykowskiRosemary WyseYoshiyuki Yamada
• Organismes : Institut de Planétologie et d'Astrophysique de Grenoble School of Physics [Sydney] Centro de Astrofísica e Gravitação [Instituto Superior Técnico, Lisboa] = Center for Astrophysics and Gravitation [Lisbon] Centro de Astrofísica e Gravitação [Instituto Superior Técnico, Lisboa] = Center for Astrophysics and Gravitation [Lisbon] Queen Mary University of London Stockholm University Ecole Polytechnique Fédérale de Lausanne Max Planck Institute for Astrophysics UNINOVA / CTS, Campus FCT/UNL Stockholm University University of Texas at Austin [Austin] Observatoire Astronomique de l'Université de Genève Universität zu Köln = University of Cologne Institut d'astrophysique spatiale Institut d'Astrophysique de Paris University of Texas at Austin [Austin] Aurora Technology BV Jet Propulsion Laboratory INAF - Osservatorio Astrofisico di Torino Stockholm University Centro de Astrobiologia [Madrid] INAF - Osservatorio Astrofisico di Torino Universidad de Granada = University of Granada Universität Wien = University of Vienna Department of Astronomy [Seattle] INAF - Osservatorio Astrofisico di Torino Laboratoire d'Astrophysique de Bordeaux [Pessac] Harvard-Smithsonian Center for Astrophysics Centro de Astrofísica e Gravitação [Instituto Superior Técnico, Lisboa] = Center for Astrophysics and Gravitation [Lisbon] INAF - Osservatorio Astronomico di Roma University of Antofogasta The University of Sydney Universidade de Coimbra = University of Coimbra [Portugal] INAF - Osservatorio Astrofisico di Torino Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics INAF - Osservatorio Astrofisico di Torino University of Colorado [Boulder] Skane University Hospital [Lund] Dipartimento di Fisica [Torino] Istituto Nazionale di Fisica Nucleare, Sezione di Torino Copernicus Astronomical Center of the Polish Academy of Sciences Leiden Observatory [Leiden] Chalmers University of Technology [Gothenburg, Sweden] INAF - Osservatorio Astrofisico di Torino Faculdade de Engenharia da Universidade do Porto Université du Michigan = University of Michigan [Ann Arbor] Stockholm University Centro de Astrofísica e Gravitação [Instituto Superior Técnico, Lisboa] = Center for Astrophysics and Gravitation [Lisbon] Jet Propulsion Laboratory The Open University [Milton Keynes, UK] The University of Edinburgh Institute of Astronomy [Cambridge] Lund Observatory The Open University [Milton Keynes, UK] Niels Bohr Institute [Copenhagen] Institut de Ciencies del Cosmos Lohrmann Observatory Observatoire astronomique de Strasbourg Institut de Mécanique Céleste et de Calcul des Ephémérides INAF - Osservatorio Astrofisico di Torino Systèmes de Référence Temps Espace Institut de Ciencies del Cosmos ESA - ESTEC (Netherlands) Centro de Astrofísica e Gravitação [Instituto Superior Técnico, Lisboa] = Center for Astrophysics and Gravitation [Lisbon] Centro de Astrofísica e Gravitação [Instituto Superior Técnico, Lisboa] = Center for Astrophysics and Gravitation [Lisbon] Jet Propulsion Laboratory The Open University [Milton Keynes, UK] Columbia State Community College Laboratoire Univers et Théories Dipartimento di Fisica [Torino] Istituto Nazionale di Fisica Nucleare, Sezione di Torino Institut de Ciencies del Cosmos Thales Alenia Space [Toulouse] Universität Heidelberg [Heidelberg] = Heidelberg University Laboratoire Univers et Théories The University of Queensland Imperial College London Observatoire astronomique de Strasbourg Instituto de Astrofísica e Ciências do Espaço Faculdade de Engenharia da Universidade do Porto Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Space Sciences Laboratory [Berkeley] Jet Propulsion Laboratory Planetary Science Institute [Tucson] Université du Michigan = University of Michigan [Ann Arbor] Institute of Astronomy [Cambridge] Space Telescope Science Institute Space Science and Technology Department [Didcot] The Open University [Milton Keynes, UK] Astronomical Observatory [Warsaw] Johns Hopkins University [Baltimore] Department of Physics [Kyoto]
• Publié dans Experimental Astronomy le 29/10/2020

---

Résumé : Sky survey telescopes and powerful targeted telescopes play complementary roles in astronomy. In order to investigate the nature and characteristics of the motions of very faint objects, a flexibly-pointed instrument capable of high astrometric accuracy is an ideal complement to current astrometric surveys and a unique tool for precision astrophysics. Such a space-based mission will push the frontier of precision astrometry from evidence of Earth-mass habitable worlds around the nearest stars, to distant Milky Way objects, and out to the Local Group of galaxies. As we enter the era of the James Webb Space Telescope and the new ground-based, adaptive-optics-enabled giant telescopes, by obtaining these high precision measurements on key objects that Gaia could not reach, a mission that focuses on high precision astrometry science can consolidate our theoretical understanding of the local Universe, enable extrapolation of physical processes to remote redshifts, and derive a much more consistent picture of cosmological evolution and the likely fate of our cosmos. Already several missions have been proposed to address the science case of faint objects in motion using high precision astrometry missions: NEAT proposed for the ESA M3 opportunity, micro-NEAT for the S1 opportunity, and Theia for the M4 and M5 opportunities. Additional new mission configurations adapted with technological innovations could be envisioned to pursue accurate measurements of these extremely small motions. The goal of this White Paper is to address the fundamental science questions that are at stake when we focus on the motions of faint sky objects and to briefly review instrumentation and mission profiles.

---

Fichiers liés : EXPA_malbet_SI_Voyage2050.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 03/09/2021
• Auteurs : Yassir BenhimaPhilippe SénacJean-Pierre van Staëvel
• Organismes : Histoire, Archéologie et Littératures des mondes chrétiens et musulmans médiévaux Université Sorbonne Nouvelle - Paris 3 Centre de Recherche Roland Mousnier Histoire et Civilisation Université Sorbonne Nouvelle - Paris 3 ORIENT ET MÉDITERRANÉE : Textes, Archéologie, Histoire Université Paris 1 Panthéon-Sorbonne
• Publié dans Revue des Mondes Musulmans et de la Méditerranée le 28/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 03/09/2021
• Auteurs : Boun Kim TanMathieu ChalouniDominique Salmon CeronAlexandre CinaudLaure EsterleMarc Arthur LokoChristine KatlamaIsabelle Poizot-MartinDidier NeauJulie ChasPhilippe MorlatEric RosenthalKarine LacombeAlissa NaqviKarl BarangeOlivier BouchaudAnne GervaisCaroline Lascoux-CombeDaniel GaripuyLaurent AlricCécile GoujardPatrick MiailhesHugues AumaitreClaudine DuvivierAnne SimonJose-Luis Lopez-ZaragozaDavid ZucmanFrançois RaffiEstibaliz LazaroDavid ReyLionel PirothFrançois BouéCamille GilbertFirouzé Bani-SadrFrançois DabisPhilippe SogniLinda WittkopFranck Boccara
• Organismes : Hôpital Cochin [AP-HP] Hôpitaux Universitaires Paris Centre Université Paris Descartes - Paris 5 Team MORPH3EUS Université de Bordeaux Hôpitaux Universitaires Paris Centre Université Paris Descartes - Paris 5 Université Paris Descartes - Paris 5 Hôtel-Dieu Team MORPH3EUS Université de Bordeaux Team MORPH3EUS Université de Bordeaux CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique Hôpital Sainte-Marguerite [CHU - APHM] Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale Hôpital Pellegrin Université de Bordeaux CHU Tenon [AP-HP] Team MORPH3EUS Université de Bordeaux Hôpital Saint-André [Bordeaux] Hôpital l'Archet Université de Nice Sophia-Antipolis Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Saint-Antoine [AP-HP] Hôpital l'Archet Centre Hospitalier Universitaire de Toulouse Hôpital Avicenne [AP-HP] Université Sorbonne Paris Nord AP-HP - Hôpital Bichat - Claude Bernard [Paris] Hopital Saint-Louis [AP-HP] Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Toulouse Pharmacochimie et Biologie pour le Développement Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Université Paris-Saclay Hôpital de la Croix-Rousse [CHU - HCL] Centre Hospitalier Saint Jean de Perpignan Imagine - Institut des maladies génétiques (IHU) CHU Pitié-Salpêtrière [AP-HP] Hôpital Henri Mondor Hôpital Foch [Suresnes] Centre d’Investigation Clinique de Nantes Hôpital Pellegrin Hôpital Haut-Lévêque [CHU Bordeaux] Le Trait d'Union, centre de soins de l'infection par le VIH [CHU Strasbourg] CHU Dijon Université de Bourgogne Université Paris-Saclay AP-HP - Hôpital Antoine Béclère [Clamart] Team MORPH3EUS Hôpital universitaire Robert Debré [Reims] Infections Cardiovasculaires Virales et inflammation en pathologie humaine (CardioVir) UMR-S 1320 Team MORPH3EUS Université Paris Descartes - Paris 5 Hôpital Cochin [AP-HP] Immunité Innée - Innate Immunity Team MORPH3EUS Centre Hospitalier Universitaire de Bordeaux CHU Saint-Antoine [AP-HP] Université Sorbonne Paris Cité Pathologies biliaires, fibrose et cancer du foie [CRSA]
• Publié dans Clinical Infectious Diseases le 30/10/2020

---

Résumé : Background: An increased risk of cardiovascular disease (CVD) was reported in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), without identifying factors associated with atherosclerotic CVD (ASCVD) events. Methods: HIV-HCV coinfected patients were enrolled in the Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS) CO13 HEPAVIH nationwide cohort. Primary outcome was total ASCVD events. Secondary outcomes were coronary and/or cerebral ASCVD events, and peripheral artery disease (PAD) ASCVD events. Incidences were estimated using the Aalen-Johansen method. Factors associated with ASCVD were identified using cause-specific Cox proportional hazards models. Results: At baseline, median age of the study population (N = 1213) was 45.4 (interquartile range [IQR] 42.1-49.0) years and 70.3% were men. After a median follow-up of 5.1 (IQR 3.9-7.0) years, the incidence was 6.98 (95% confidence interval [CI], 5.19-9.38) per 1000 person-years for total ASCVD events, 4.01 (2.78-6.00) for coronary and/or cerebral events, and 3.17 (2.05-4.92) for PAD ASCVD events. Aging (hazard ratio [HR] 1.06; 95% CI, 1.01-1.12), prior CVD (HR 8.48; 95% CI, 3.14-22.91), high total cholesterol (HR 1.43; 95% CI, 1.11-1.83), high-density lipoprotein cholesterol (HR 0.22; 95% CI, 0.08-0.63), statin use (HR 3.31; 95% CI, 1.31-8.38), and high alcohol intake (HR 3.18; 95% CI, 1.35-7.52) were independently associated with total ASCVD events, whereas undetectable baseline viral load (HR 0.41, 95% CI, 0.18-0.96) was associated with coronary and/or cerebral events. Conclusions: HIV-HCV coinfected patients experienced a high incidence of ASCVD events. Some traditional cardiovascular risk factors were the main determinants of ASCVD. Controlling cholesterol abnormalities and maintaining undetectable HIV RNA are essential to control cardiovascular risk.

---

Fichiers liés : ciaa1014.pdf

---

Source